BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 11107117)

  • 1. BIN1 inhibits colony formation and induces apoptosis in neuroblastoma cell lines with MYCN amplification.
    Hogarty MD; Liu X; Thompson PM; White PS; Sulman EP; Maris JM; Brodeur GM
    Med Pediatr Oncol; 2000 Dec; 35(6):559-62. PubMed ID: 11107117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features.
    Tajiri T; Liu X; Thompson PM; Tanaka S; Suita S; Zhao H; Maris JM; Prendergast GC; Hogarty MD
    Clin Cancer Res; 2003 Aug; 9(9):3345-55. PubMed ID: 12960121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MycN sensitizes neuroblastoma cells for drug-triggered apoptosis.
    Fulda S; Lutz W; Schwab M; Debatin KM
    Med Pediatr Oncol; 2000 Dec; 35(6):582-4. PubMed ID: 11107122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas.
    Wang Q; Hii G; Shusterman S; Mosse Y; Winter CL; Guo C; Zhao H; Rappaport E; Hogarty MD; Maris JM
    Cancer Res; 2003 Apr; 63(7):1631-5. PubMed ID: 12670915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Losses of the tumor suppressor BIN1 in breast carcinoma are frequent and reflect deficits in programmed cell death capacity.
    Ge K; Duhadaway J; Sakamuro D; Wechsler-Reya R; Reynolds C; Prendergast GC
    Int J Cancer; 2000 Feb; 85(3):376-83. PubMed ID: 10652430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of apoptosis and differentiation in neuroblastoma and astrocytoma cells by the overexpression of Bin1, a novel Myc interacting protein.
    Galderisi U; Di Bernardo G; Cipollaro M; Jori FP; Piegari E; Cascino A; Peluso G; Melone MA
    J Cell Biochem; 1999 Sep; 74(3):313-22. PubMed ID: 10412034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.
    Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M
    Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The requirement for evasion of programmed cell death in neuroblastomas with MYCN amplification.
    Hogarty MD
    Cancer Lett; 2003 Jul; 197(1-2):173-9. PubMed ID: 12880978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MYCN concurrence with SAHA-induced cell death in human neuroblastoma cells.
    Cortés C; Kozma SC; Tauler A; Ambrosio S
    Cell Oncol (Dordr); 2015 Oct; 38(5):341-52. PubMed ID: 26306783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MYCN sensitizes human neuroblastoma to apoptosis by HIPK2 activation through a DNA damage response.
    Petroni M; Veschi V; Prodosmo A; Rinaldo C; Massimi I; Carbonari M; Dominici C; McDowell HP; Rinaldi C; Screpanti I; Frati L; Bartolazzi A; Gulino A; Soddu S; Giannini G
    Mol Cancer Res; 2011 Jan; 9(1):67-77. PubMed ID: 21173028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3.
    Fabian J; Lodrini M; Oehme I; Schier MC; Thole TM; Hielscher T; Kopp-Schneider A; Opitz L; Capper D; von Deimling A; Wiegand I; Milde T; Mahlknecht U; Westermann F; Popanda O; Roels F; Hero B; Berthold F; Fischer M; Kulozik AE; Witt O; Deubzer HE
    Cancer Res; 2014 May; 74(9):2604-16. PubMed ID: 24419085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological diagnosis for neuroblastoma using the combination of highly sensitive analysis of prognostic factors.
    Tajiri T; Tanaka S; Higashi M; Kinoshita Y; Takahashi Y; Tatsuta K; Suita S
    J Pediatr Surg; 2006 Mar; 41(3):560-6. PubMed ID: 16516635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NCYM promotes calpain-mediated Myc-nick production in human MYCN-amplified neuroblastoma cells.
    Shoji W; Suenaga Y; Kaneko Y; Islam SM; Alagu J; Yokoi S; Nio M; Nakagawara A
    Biochem Biophys Res Commun; 2015 Jun; 461(3):501-6. PubMed ID: 25896758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of mir-21, which is up-regulated during MYCN knockdown-mediated differentiation, does not prevent differentiation of neuroblastoma cells.
    Buechner J; Henriksen JR; Haug BH; Tømte E; Flaegstad T; Einvik C
    Differentiation; 2011 Jan; 81(1):25-34. PubMed ID: 20980091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BIN1 is a novel MYC-interacting protein with features of a tumour suppressor.
    Sakamuro D; Elliott KJ; Wechsler-Reya R; Prendergast GC
    Nat Genet; 1996 Sep; 14(1):69-77. PubMed ID: 8782822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different effects of TrkA expression in neuroblastoma cell lines with or without MYCN amplification.
    Eggert A; Ho R; Ikegaki N; Liu XG; Brodeur GM
    Med Pediatr Oncol; 2000 Dec; 35(6):623-7. PubMed ID: 11107132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A genome-wide search for promoters that respond to increased MYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma.
    Shohet JM; Ghosh R; Coarfa C; Ludwig A; Benham AL; Chen Z; Patterson DM; Barbieri E; Mestdagh P; Sikorski DN; Milosavljevic A; Kim ES; Gunaratne PH
    Cancer Res; 2011 Jun; 71(11):3841-51. PubMed ID: 21498633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma.
    Lau DT; Flemming CL; Gherardi S; Perini G; Oberthuer A; Fischer M; Juraeva D; Brors B; Xue C; Norris MD; Marshall GM; Haber M; Fletcher JI; Ashton LJ
    Oncotarget; 2015 Jun; 6(17):15510-23. PubMed ID: 25860940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Caspase-9 and Apaf-1 are expressed and functionally active in human neuroblastoma tumor cell lines with 1p36 LOH and amplified MYCN.
    Teitz T; Wei T; Liu D; Valentine V; Valentine M; Grenet J; Lahti JM; Kidd VJ
    Oncogene; 2002 Mar; 21(12):1848-58. PubMed ID: 11896617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vasoactive intestinal peptide decreases MYCN expression and synergizes with retinoic acid in a human MYCN-amplified neuroblastoma cell line.
    Chevrier L; Meunier AC; Cochaud S; Muller JM; Chadéneau C
    Int J Oncol; 2008 Nov; 33(5):1081-9. PubMed ID: 18949372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.